Differences in concomitant medication use, particularly administration of strong CYP3A4 inducers in MTC patients, could have resulted in the increased cabozantinib clearance observed in the MTC patient population. The gene discussed is CYP3A4; the disease is medullary thyroid gland carcinoma.